EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation

Farah Abuazzam, Casey Dubrawka iD, Tarek Abdulhadi iD, Gwendolyn Amurao, Louai Alrata iD, Dema Yaseen Alsabbagh iD, Omar Alomar iD, Tarek Alhamad iD

Journal of Clinical Medicine · 26.07.2023 · 12 (15) · 4916

DOI: 10.3390/jcm12154916 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.07.2023. Verfasst von Farah Abuazzam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the advances in immunosuppressive medications, antibody-mediated rejection (AMR) continues to be a major cause of kidney allograft failure and remains a barrier to improving long-term allograft survival. Recently, there have been significant advances in the understanding of the pathophysiological process of AMR, along with the development of new therapeutic options. Additionally, surveillance protocols with donor-derived cell-free DNA and gene profile testing have been established, leading to the early detection of AMR. A multitude of clinical trials are ongoing, opening numerous opportunities for improving outcome in kidney transplant recipients. In this brief review, we discuss the emerging therapies for managing both active and chronic active AMR and highlight the ongoing clinical trials.

Schlagwörter

Stichwörter der Autor:innen

T-cell mediated rejectionallograft rejectionantibody-mediated rejectionkidney graft functionkidney transplantmix rejectiontransplant immunology

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Department of Pharmacy, Barnes Jewish Hospital, St. Louis, MO 63110, USA.
  • Transplant Epidemiology Research Collaboration (TERC), Institute of Public Health, Washington University School of Medicine, St. Louis, MO 63110, USA.

ORCID-Profile: Casey Dubrawka, Tarek Abdulhadi, Louai Alrata, Dema Yaseen Alsabbagh, Omar Alomar, Tarek Alhamad

Zitieren

APA

Abuazzam, F., Dubrawka, C., Abdulhadi, T., Amurao, G., Alrata, L., Yaseen Alsabbagh, D., Alomar, O., & Alhamad, T. (2023). Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation. Journal of Clinical Medicine, 12(15), 4916. https://doi.org/10.3390/jcm12154916

Vancouver

Abuazzam F, Dubrawka C, Abdulhadi T, Amurao G, Alrata L, Yaseen Alsabbagh D, et al. Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation. Journal of Clinical Medicine. 2023;12(15):4916. doi:10.3390/jcm12154916

BibTeX
@article{Abuazzam2023,
  author = {Abuazzam, Farah and Dubrawka, Casey and Abdulhadi, Tarek and Amurao, Gwendolyn and Alrata, Louai and Yaseen Alsabbagh, Dema and Alomar, Omar and Alhamad, Tarek},
  title = {Emerging Therapies for Antibody-Mediated Rejection in Kidney Transplantation},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {15},
  pages = {4916},
  doi = {10.3390/jcm12154916}
}
Kostenlos starten →